. Prolonged diabetes causes major complications in tissues which do not require insulin for transport of glucose, including hyperglycemia-induced neuropathy, retinopathy, nephropathy, epitheliopathy, and cataractogenesis. However, the mechanisms of hyperglycemia-induced cell injury are poorly understood. The first enzyme of the polyol pathway, aldose reductase (AR), has been implicated in diabetic complications because use of aldose reductase inhibitors (ARIs) prevents, reduces, or, to some extent, reverses hyperglycemia-induced cataractogenesis, neuropathy, and retinopathy. Increased AR activity in hyperglycemia has been attributed to activation and/or induction of the enzyme. However, neither the mechanisms of induction nor of activation are well understood. In addition, all the ARIs presently known inhibit both AR and aldehyde reductase, and both enzymes have overlapping substrate specificities. Aldehyde reductase may be important for reducing biogenic amines and a number of dicarbonyl compounds. Therefore, for understanding and managing diabetic complications, it is necessary to elucidate the physicochemical properties of AR and its regulation and physiological roles, along with the properties of aldehyde reductase. We propose to continue our studies on the structural and kinetic properties of AR and aldehyde reductase, and on the regulation of AR under normo-glycemic and hyperglycemic conditions. We will determine the chemical catalytic mechanisms of aldehyde reduction by these enzymes, their mechanisms of inhibitor and substrate interactions, and the sequences of their substrate binding sites. The residues involved in substrate and inhibitor binding, inactivation of aldose reductase and in the chemical reactions will be studied by using site directed mutagenesis. The AR activity increases in hyperglycemia, and the reaction kinetics and inhibitor sensitivity also change. The roles of oxidation, glycation and induction will be examined to understand the mechanism(s) of activation, deactivation and increased transcription of AR during hyperglycemia. We will use a hyperglycemic animal model and cultured neuroblastoma cells to assess the contributions of oxidative stress to tissue injury, perhaps caused by increased free radicals and/or decreased defense capacity against oxidants and polyols. Our studies will help in understanding the role of AR in the etiology of diabetic complications, and will provide a logical approach to treating or preventing the development of such complications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK036118-09
Application #
2443982
Study Section
Visual Sciences A Study Section (VISA)
Program Officer
Linder, Barbara
Project Start
1987-04-01
Project End
1998-06-30
Budget Start
1997-07-18
Budget End
1998-06-30
Support Year
9
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Biochemistry
Type
Schools of Medicine
DUNS #
041367053
City
Galveston
State
TX
Country
United States
Zip Code
77555
Awasthi, Yogesh C; Ramana, Kota V; Chaudhary, Pankaj et al. (2017) Regulatory roles of glutathione-S-transferases and 4-hydroxynonenal in stress-mediated signaling and toxicity. Free Radic Biol Med 111:235-243
Shoeb, Mohammad; Ansari, Naseem H; Srivastava, Satish K et al. (2014) 4-Hydroxynonenal in the pathogenesis and progression of human diseases. Curr Med Chem 21:230-7
Yadav, Umesh C S; Srivastava, Satish K; Ramana, Kota V (2012) Prevention of VEGF-induced growth and tube formation in human retinal endothelial cells by aldose reductase inhibition. J Diabetes Complications 26:369-77
Kalariya, Nilesh M; Shoeb, Mohammad; Ansari, Naseem H et al. (2012) Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 53:3431-40
Pandey, Saumya; Srivastava, Satish K; Ramana, Kota V (2012) A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases. Expert Opin Investig Drugs 21:329-39
Shoeb, Mohammad; Yadav, Umesh C S; Srivastava, Satish K et al. (2011) Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages. Free Radic Biol Med 51:1686-96
Tammali, Ravinder; Saxena, Ashish; Srivastava, Satish K et al. (2011) Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells. J Biol Chem 286:24089-100
Srivastava, Satish K; Yadav, Umesh C S; Reddy, Aramati B M et al. (2011) Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem Biol Interact 191:330-8
Reddy, Aramati B M; Tammali, Ravinder; Mishra, Rakesh et al. (2011) Aldose reductase deficiency protects sugar-induced lens opacification in rats. Chem Biol Interact 191:346-50
Tammali, Ravinder; Reddy, Aramati B M; Saxena, Ashish et al. (2011) Inhibition of aldose reductase prevents colon cancer metastasis. Carcinogenesis 32:1259-67

Showing the most recent 10 out of 119 publications